Evidence map›Paper›PMID 26176309›Full record

Observational studyBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica2015

Association of body mass index with disease severity and prognosis in patients with non-cystic fibrosis bronchiectasis.

Q Qi, T Li, J C Li, Y Li

Registry-linked trialOpen access · goldAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06344000 (A Study of the Association Between Progression and Nutritional Status in Bronchiectasis), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06344000 recruitingnot on this mapstarted 2024, after this paper: background citation

A Study of the Association Between Progression and Nutritional Status in Bronchiectasis

TypeobservationalSponsorUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyRan2024 to 2027Enrolled300ConditionsBronchiectasisArmsinapplicable
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Diagnosis and management of non-cystic fibrosis bronchiectasis.Clinical medicine (London, England) · 2021
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Nutrition and Markers of Disease Severity in Patients With Bronchiectasis.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2020
    Article
  14. BMJ open · 2018
    Article
  15. Article
  16. Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Q QiDepartment of Respirology, Qilu Hospital, Shandong University, Shandong Province, Jinan, China.
T LiDepartment of Respirology, Qilu Hospital, Shandong University, Shandong Province, Jinan, China.
J C LiNeurosurgical Intensive Care Unit, First Affiliated Hospital,, Sun Yat-sen University, Guangdong Province, Guangzhou, China.
Y LiDepartment of Respirology, Qilu Hospital, Shandong University, Shandong Province, Jinan, China.
Shandong University · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of this observational, multicenter study was to evaluate the association of body mass index (BMI) with disease severity and prognosis in patients with non-cystic fibrosis bronchiectasis. A total of 339 patients (197 females, 142 males) diagnosed with non-cystic fibrosis bronchiectasis by high-resolution computed tomography were classified into four groups: underweight (BMI<18.5 kg/m2), normal weight (18.5≤BMI<25.0 kg/m2), overweight (25.0≤BMI<30.0 kg/m2), and obese (BMI≥30.0 kg/m2). Clinical variables expressing disease severity were recorded, and acute exacerbations, hospitalizations, and survival rates were estimated during the follow-up period. The mean BMI was 21.90 kg/m2. The underweight group comprised 28.61% of all patients. BMI was negatively correlated with acute exacerbations, C-reactive protein, erythrocyte sedimentation rate, radiographic extent of bronchiectasis, and chronic colonization by P. aeruginosa and positively correlated with pulmonary function indices. BMI was a significant predictor of hospitalization risk independent of relevant covariates. The 1-, 2-, 3-, and 4-year cumulative survival rates were 94%, 86%, 81%, and 73%, respectively. Survival rates decreased with decreasing BMI (χ2=35.16, P<0.001). The arterial carbon dioxide partial pressure, inspiratory capacity, age, BMI, and predicted percentage of forced expiratory volume in 1 s independently predicted survival in the Cox proportional hazard model. In conclusion, an underweight status was highly prevalent among patients with non-cystic fibrosis bronchiectasis. Patients with a lower BMI were prone to developing more acute exacerbations, worse pulmonary function, amplified systemic inflammation, and chronic colonization by P. aeruginosa. BMI was a major determinant of hospitalization and death risks. BMI should be considered in the routine assessment of patients with non-cystic fibrosis bronchiectasis.

Indexed as

Body Mass IndexBronchiectasisFemaleHumansMaleMiddle AgedPrognosisSeverity of Illness IndexSurvival RateTomography, X-Ray Computed

Identifiers

PMID26176309
PMCPMC4541691
OpenAlexW1574867479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.